The Central Drugs Standard Control Organization (CDSCO) has granted permission to the Christian Medical College, Vellore to conduct phase-I...

South Africa has been struggling with its plans to achieve the herd immunity through vaccinations, with widespread vaccine hesitancy, large...

India’s drug regulator has asked for the immunogenicity data from Serum Institute as the vaccine is not yet appoved by the US FDA.

Covaxin contains dead virus of Covid which triggers the immune system to draw up a defense system against Covid while Covishield is vector ...

The study titled ‘Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime...

Zydus had applied for emergency use authorisation (EUA) for its vaccine on July 1, but it is yet to be taken up by the subject expert commi...

One of the six, Hetero Biopharma, had last fortnight obtained clearance from the subject expert committee under India’s drug controller to ...

India’s first indigenous Covid-19 vaccine Covaxin, codenamed BBV152, is safe, immunogenic and has no serious adverse effects, medical journ...

Drugs Controller General of India (DCGI) had on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, an...

The subject expert committee had given conditional nod to both the vaccines and these were awaiting the drug regulator's approval.

A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people,...

Earlier this week, a committee of experts had deferred a decision on the request of SII to start trials and asked the company to amend its ...

SII's Oxford vaccine is one of the front runners in the fight against Covid-19. On July 20, researchers at the University of Oxford publish...

According to the minutes of the meeting, the SEC has asked Serum to distribute clinical trial sites pan India, demarcate the phase II and P...

Zydus Cadila's move to begin human trials of its indigenously developed vaccine candidate for COVID-19 is an important milestone for an 'At...

‘We did a detailed 28-day toxicity study in two different animal species’

Hilleman Labs received approvals to conduct phase I and II clinical trials for the two vaccines in recent weeks from Directorate General of...